Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

VivaMab and ADC Therapeutics Announce Antibody Licensing Deal

Published: Tuesday, June 25, 2013
Last Updated: Tuesday, June 25, 2013
Bookmark and Share
Licensing deal for novel ADC candidate to target hematologic cancers.

VivaMab and ADC Therapeutics Sarl have announced a licensing deal for a novel antibody against an undisclosed hematological cancer target.

Under the terms of the deal, ADC Therapeutics has licensed a VivaMab antibody (VM101) produced using BioAtla’s Express Humanization™, Comprehensive Positional Evolution™, Combinatorial Protein Synthesis™ affinity and functional maturation technology platforms.

VM101 has been combined with a third-generation cytotoxic pyrrolobenzodiazepine (PBD)-based warhead and proprietary linker technology to form a novel ADC, which has already been shown to have powerful in vivo efficacy in established models for normally intractable hematological cancer indications.

ADC Therapeutics plans to initiate pre-IND development of this proprietary ADC immediately, in parallel with its other advanced ADC programs.

VivaMab will provide development support and will receive a share of potential milestones and royalties on the drug. Financial terms were not disclosed and remain confidential.

Dr. William Boyle, President of VivaMab said: “The BioAtla platform has generated a superior internalizing antibody to the target of interest, allowing us to generate and develop an ADC drug candidate for hematologic cancers. The combination of a uniquely potent BioAtla antibody with a potent drug conjugate, or warhead, is likely to enhance therapeutic outcomes in its target indication.”

Dr. Peter B. Corr, Chairman of ADC Therapeutics and Managing General Partner of Auven Therapeutics said: “PBD-antibody conjugates are the most promising next-generation ADCs. The target disease for this ADC is particularly sensitive to our PBD technology, with its functionally optimized conjugation and pharmaceutical properties that maintain activity in cancers resistant to other therapies including earlier generations of ADCs. We are very pleased to be working with VivaMab to bring this potentially exciting cancer therapeutic into clinical development.”

Results presented at the 2013 American Association for Cancer Research by BioAtla and Spirogen showed positive data describing the potent ADC activity which resulted from the combination of BioAtla’s functionally and CIAO!™ evolved antibody with Spirogen’s PBD-derived conjugate.

The pre-clinical studies, that evaluated in vivo performance against a hematologic cancer target, showed complete responses at low doses, and at low drug-antibody ratios, in each of the tumor types studied.

The PBD dimers were not found to be cross-resistant with widely used chemotherapeutic agents.

Dr. Jay M. Short, CEO and Chairman of BioAtla sees future opportunities to pursue ADCs: “By creating an antibody that is optimized for expression, target binding and potency, BioAtla and ADCT are paving the way to make powerful next generation cancer drugs with the potential to save lives.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos